The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
Investigators teased out imaging signals and underlying biology that can differentiate the subset of brain cancers for which tumor DNA can be detected in blood.
In a new study, using larger numbers of patient-specific mutations helped better detect residual disease in breast cancer patients' blood after treatment.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
Investigators have developed an approach called RAMP-Seq in which targeted radiation of a suspicious lesion vastly increase levels ctDNA, aiding detection and allowing genotyping.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
